Fibromyalgia is a clinical syndrome wherein the patient experiences generalized pain and fatigue that cannot be explained by the presence of any other disorder.
It is often considered to be psychosomatic or psychogenic in nature.
It is found in approximately 2% of the population and the prevalence increases with age, most common in women 20-55 year of age


  • A syndrome of chronic diffuse pain syndromes that affect muscles, soft tissues (eg tendons, ligaments) and other somatic symptoms
  • May be related to alterations in CNS pain processing
  • Found in approx 2% of the population & the prevalence increases w/ age, most common in women 20-55 yr of age


  • Etiology of pain is not known; often considered to be psychosomatic or psychogenic in nature

Signs and Symptoms

Clinical Manifestations

  • Widespread pain - initially localized then later involving multiple sites, predominantly involving muscles, musculoskeletal junctions & joints
  • Fatigue
  • Disrupted unrefreshed sleep
  • Cognitive disturbances - often referred to as “fibro fog”
  • Mood disturbances
  • Somatic symptoms (eg irritable bowel syndrome, severe menstrual pain, myofascial facial pain)
  • Non-pain related symptoms (sexual dysfunction)

Associated Symptoms

  • Paresthesias
  • Headache - include migraine & muscular or tension type
  • Anxiety & depression
  • Allergic symptoms & multiple chemical sensitivity
  • Weight disturbances
  • Pelvic pain, urinary frequency & urgency, & dysmenorrhea
  • Symptoms of irritable bowel syndrome
  • Sjogren symptoms
  • Raynaud’s phenomenon
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Mar 2018
Abaloparatide appears to produce significant increases in the bone mass density (BMD), as well as nominal reductions in fractures, in very elderly women with osteoporosis, with a safety profile similar to that in the overall study population, according to a posthoc analysis of the phase III ACTIVE trial.